Edgewise Therapeutics EWTX 深 沪
等待开盘 12-17 09:30:00 美东时间
22.77
-1.170
-4.89%
华盛通- 最 高24.31
- 今 开23.81
- 成交量 133.91万股
- 最 低 22.55
- 昨 收 23.94
- 总市值 23.91亿
- 52周最高 30.48
- 市盈率 静 --
- 换手率 1.28%
- 52周最低 10.60
- 委 比 2.01%
- 总股本 1.05亿
- 历史最高 40.49
- 量 比 0.71
- 振 幅 7.35%
- 历史最低 5.12
- 每 手 1
- 风险率 5.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Edgewise Therapeutics Appoints Christopher Martin to Board
Edgewise Therapeutics ( ($EWTX) ) has shared an announcement. Edgewise Therapeu...
11-21 06:26
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
美股周涨跌榜 | 新药取得重大突破！COGT周涨超126%；生物制药公司Cidara周涨逾108%，获默沙东收购
新药取得重大突破！COGT周涨超126%；生物制药公司Cidara周涨逾108%，获默沙东92亿美元收购；REAL周涨超26%，Q3业绩超预期>>
11-15 10:30
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel t...
11-12 21:00
Edgewise Therapeutics Appoints New Chief Financial Officer
An announcement from Edgewise Therapeutics ( ($EWTX) ) is now available. On Nov...
11-11 06:58
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $32
Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $35 to $32.
11-07 23:05
Edgewise Therapeutics Q3 EPS $(0.39) Beats $(0.40) Estimate
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.40) by 1.76 percent. This is a 14.71 percent decrease over losses of $(0.34) per share
11-06 21:30
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel th...
10-03 04:01
